David Landman
Overview
Explore the profile of David Landman including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
51
Citations
2256
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Gupta A, Malik S, Kaminski M, Landman D, Quale J
Microb Drug Resist
. 2022 Apr;
28(4):419-424.
PMID: 35451880
Infections due to extended-spectrum β-lactamase (ESBL)-producing Enterobacterales are an increasingly common problem. For many of these infections, no oral treatment options are available. The activity of amoxicillin-clavulanate combined with ceftibuten...
2.
Gupta A, Landman D, Quale J
J Antimicrob Chemother
. 2022 Feb;
77(5):1282-1285.
PMID: 35134942
Objectives: Cefiderocol maintains activity against most MDR Gram-negative pathogens including Pseudomonas aeruginosa. In laboratory-derived isolates, down-regulation of TonB-dependent siderophore receptors have been implicated in resistance to cefiderocol. Methods: In this...
3.
Episcopia B, Gupta A, Fornek M, Kaminski M, Malik S, Sunny S, et al.
Am J Infect Control
. 2021 Mar;
49(10):1262-1266.
PMID: 33716096
Background: Healthcare facility-onset Clostridioides difficile infection is associated with adverse clinical outcomes and hospital reimbursement. A four-year review involving eleven hospitals of the NYC Health + Hospital system was undertaken....
4.
Kaminski M, Episcopia B, Malik S, Fornek M, Landman D, Xavier G, et al.
Infect Control Hosp Epidemiol
. 2020 Nov;
42(7):842-846.
PMID: 33208201
Background: Central-line bloodstream infections (CLABSIs) and catheter-associated urinary tract infections (CAUTIs) negatively impact clinical outcomes and hospital reimbursement. In this report, 4 year trends involving 11 hospitals in New York...
5.
Malik S, Kaminski M, Landman D, Quale J
Antimicrob Agents Chemother
. 2020 Sep;
64(11).
PMID: 32868330
Cefiderocol is a siderophore cephalosporin active against many multidrug-resistant (MDR) Gram-negative pathogens. We examined the resistance mechanisms in 12 strains with cefiderocol MICs ranging from ≤0.03 to >32 μg/ml. Cefiderocol...
6.
Iregui A, Landman D, Quale J
Microb Drug Resist
. 2020 Jun;
27(2):190-195.
PMID: 32580619
Antibiotic-resistant Enterobacteriaceae and are problematic pathogens, with few treatment options for multidrug-resistant (MDR)- and few oral options for extended spectrum β-lactamase (ESBL)-producing and MDR-Enterobacteriaceae. Omadacycline, a newer tetracycline derivative, has...
7.
Iregui A, Khan Z, Landman D, Quale J
Microb Drug Resist
. 2020 Feb;
26(7):722-726.
PMID: 32031915
Therapeutic options for the treatment of infections owing to multidrug-resistant Gram-negative pathogens are often limited. Cefiderocol is a novel siderophore cephalosporin with activity against Gram-negative pathogens, including many multidrug-resistant strains....
8.
Iregui A, Khan Z, Landman D, Quale J
Antimicrob Agents Chemother
. 2019 Oct;
64(1).
PMID: 31611363
WCK 4234 is a novel diazabicyclooctane with potent inhibitory activity against class A and D carbapenemases and class C enzymes. We examined the activity of meropenem plus WCK 4234 (4...
9.
Iregui A, Khan Z, Malik S, Landman D, Quale J
Clin Infect Dis
. 2019 Aug;
70(8):1758-1760.
PMID: 31412357
Delafloxacin is an option for infections due to methicillin-resistant Staphylococcus aureus. In 2017, 22% of isolates from 7 hospitals in Brooklyn, New York, were nonsusceptible to delafloxacin. Isolates belonging to...
10.
Khan Z, Iregui A, Landman D, Quale J
J Antimicrob Chemother
. 2019 Jul;
74(10):2938-2942.
PMID: 31298277
Background: The combination of cefepime and zidebactam (WCK5222), a novel β-lactam enhancer, has demonstrated activity against a wide variety of Gram-negative pathogens and is currently under clinical evaluation. Objectives: To...